Mad in America

OCTOBER 24, 2024

The authors refused to withdraw the article, which resulted in a five-month battle where they needed legal assistance from their university and from Germany where the publisher is located. 18] Goldney had received “gold” “from a number of pharmaceutical companies.” There was nothing defamatory in the content. No surprise there.

Pharmaceutical 144

Pharmaceutical Reporting Controlling Correspondence 144

Mad in America

JANUARY 29, 2024

If one reads the ADM literature, it is quite apparent that the pharmaceutical industry—with the help of psychiatry—since day one has been involved in a cover up of the dangerousness of these drugs. of the drugs reviewed had two or fewer cases of violence, which is reassuring for most pharmaceuticals.

Healthcare 102

Healthcare Pharmaceutical Reporting Correspondence 102

Mad in America

OCTOBER 22, 2024

Almost every advance in technology makes corresponding demands on the human person. Psychedelics: While still controversial due to a welter of legal, cultural, and safety concerns, it now seems unavoidable that psychedelics will be part of the mental health care of the future. The servant becomes the master.

Government 128

Government Legal Pharmaceutical Correspondence 128

Mad in America

JANUARY 6, 2024

Two of the largest organizations representing therapists, the American Psychological Association and the National Association of Social Workers, took legal action. On one side are academics who conduct randomized controlled trials (RCTs), the same approach pharmaceutical companies use to establish whether drugs are effective.

Insurance 144

Insurance Consulting Advertising Controlling 144